Qiagen (NYSE:QGEN) Receives $47.71 Consensus Target Price from Analysts

Qiagen (NYSE:QGEN) has been assigned a consensus rating of “Hold” from the ten brokerages that are currently covering the stock, MarketBeat reports. Seven research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12 month target price among brokerages that have covered the stock in the last year is $47.71.

QGEN has been the topic of several recent analyst reports. Jefferies Financial Group reiterated a “buy” rating and issued a $52.50 price target (up from $40.83) on shares of Qiagen in a report on Tuesday, December 10th. Morgan Stanley reiterated an “equal weight” rating and issued a $46.67 target price (down previously from $48.61) on shares of Qiagen in a research note on Monday, January 6th. UBS Group lowered their target price on shares of Qiagen from $50.00 to $48.00 and set a “neutral” rating for the company in a research note on Friday, February 7th. Baird R W cut shares of Qiagen from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 19th. Finally, Robert W. Baird lowered shares of Qiagen from an “outperform” rating to a “neutral” rating and decreased their price objective for the company from $52.00 to $42.00 in a report on Wednesday, February 19th.

Institutional Investors Weigh In On Qiagen

Large investors have recently modified their holdings of the business. Brown Brothers Harriman & Co. purchased a new position in Qiagen during the fourth quarter valued at approximately $37,000. Geneos Wealth Management Inc. increased its holdings in shares of Qiagen by 41.5% in the 4th quarter. Geneos Wealth Management Inc. now owns 856 shares of the company’s stock valued at $38,000 after acquiring an additional 251 shares during the period. EverSource Wealth Advisors LLC increased its holdings in shares of Qiagen by 152.5% in the 4th quarter. EverSource Wealth Advisors LLC now owns 871 shares of the company’s stock valued at $39,000 after acquiring an additional 526 shares during the period. Wilmington Savings Fund Society FSB bought a new position in shares of Qiagen in the 3rd quarter worth $53,000. Finally, Smartleaf Asset Management LLC lifted its stake in shares of Qiagen by 148.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,399 shares of the company’s stock worth $63,000 after purchasing an additional 835 shares during the last quarter. Institutional investors own 70.00% of the company’s stock.

Qiagen Stock Performance

NYSE QGEN opened at $39.65 on Tuesday. The company has a market cap of $8.80 billion, a P/E ratio of 110.41, a P/E/G ratio of 2.39 and a beta of 0.44. The business’s 50 day moving average price is $40.92 and its 200-day moving average price is $42.19. Qiagen has a fifty-two week low of $37.63 and a fifty-two week high of $49.30. The company has a debt-to-equity ratio of 0.38, a quick ratio of 3.09 and a current ratio of 3.61.

Qiagen (NYSE:QGEN) last announced its earnings results on Wednesday, February 5th. The company reported $0.61 earnings per share for the quarter, beating the consensus estimate of $0.60 by $0.01. Qiagen had a net margin of 4.23% and a return on equity of 13.92%. Sell-side analysts predict that Qiagen will post 2.26 earnings per share for the current year.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.